CEO, PRESIDENT, GLAUKOS
WHY: Leads $2.5B+ valued stent device maker that treats glaucoma; also moving into pharma-based eyecare with $400M purchase of Massachusetts-based Avedro in 2019.
RECENT: Seeing outpatient surgeries, where 80% of its technologies are used, recover at a faster clip than hospital-based procedures. Involved in patent lawsuit with Irvine-based stentmaker Ivantis.
NOTABLE: Scheduled to move headquarters to 160,000-square-foot project in Aliso Viejo in 2021. IRA Capital, an Irvine-based real estate investment firm, paid $73.5M for the three-building campus in June.
